Sinopharm Group Co. Ltd. Sustainability Profile
Sinopharm Group Co. Ltd., a leading player in the pharmaceutical and healthcare industry, is headquartered in Beijing, China. Founded in 1998, the company has established itself as a pivotal force in the distribution of pharmaceuticals, medical devices, and healthcare services across various regions, including Asia, Europe, and Africa. With a diverse portfolio that includes vaccines, blood products, and diagnostic reagents, Sinopharm is renowned for its commitment to innovation and quality. The company has achieved significant milestones, such as being a key supplier of COVID-19 vaccines, which has bolstered its market position globally. Sinopharm's extensive distribution network and strong partnerships further enhance its reputation as a trusted provider in the healthcare sector, making it a cornerstone of China's pharmaceutical landscape.
DitchCarbon Score
How does Sinopharm Group Co. Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Sinopharm Group Co. Ltd.'s score of 43 is higher than 62% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Sinopharm Group Co. Ltd.'s reported carbon emissions
In 2024, Sinopharm Group Co. Ltd. reported total carbon emissions of approximately 544,381,900 kg CO2e. This figure includes 48,785,710 kg CO2e from Scope 1 emissions, 177,259,360 kg CO2e from Scope 2 emissions, and 318,336,830 kg CO2e from Scope 3 emissions. In 2023, the company’s emissions in China were about 21,973,000 kg CO2e, with Scope 1 emissions at 6,908,630 kg CO2e and Scope 2 emissions at 15,064,370 kg CO2e. Sinopharm has set ambitious climate commitments, aiming for net zero emissions by 2030 for both Scope 1 and Scope 2 emissions. This target is part of a broader strategy to achieve net zero emissions by 2050, as outlined in their long-term goals. The company’s emissions data is cascaded from its parent organization, ensuring a comprehensive approach to sustainability across its operations. Overall, Sinopharm Group Co. Ltd. is actively working towards significant reductions in its carbon footprint, aligning with global climate initiatives and demonstrating a commitment to environmental responsibility.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 30,741,540 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 88,611,470 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | - | - | 000,000,000 |
How Carbon Intensive is Sinopharm Group Co. Ltd.'s Industry?
How Carbon Intensive is Sinopharm Group Co. Ltd.'s Location?
Sinopharm Group Co. Ltd.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Sinopharm Group Co. Ltd. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
